F. Kroll

Capture compound mass spectrometry sheds light on the molecular mechanisms of liver toxicity of two Parkinson drugs.

Anna K. Schrey, Jenny J. Fischer, H. Koester, 2010, Toxicological sciences : an official journal of the Society of Toxicology.

Identification of Potential Off-target Toxicity Liabilities of Catechol-O-methyltransferase Inhibitors by Differential Competition Capture Compound Mass Spectrometry.

Anna K. Schrey, Yan Luo, M. Sefkow, 2016, Journal of medicinal chemistry.

Dabigatran and dabigatran ethyl ester: potent inhibitors of ribosyldihydronicotinamide dehydrogenase (NQO2).

Anna K. Schrey, Jenny J. Fischer, M. Sefkow, 2012, Journal of medicinal chemistry.

Dasatinib, imatinib and staurosporine capture compounds - Complementary tools for the profiling of kinases by Capture Compound Mass Spectrometry (CCMS).

Anna K. Schrey, Jenny J. Fischer, M. Sefkow, 2011, Journal of proteomics.

Comprehensive identification of staurosporine-binding kinases in the hepatocyte cell line HepG2 using Capture Compound Mass Spectrometry (CCMS).

Anna K. Schrey, J. Ungewiss, Jenny J. Fischer, 2010, Journal of proteome research.

Targeting G Protein‐Coupled Receptors by Capture Compound Mass Spectrometry: A Case Study with Sertindole

Anna K. Schrey, U. Gruber, O. Popp, 2017, Chembiochem : a European journal of chemical biology.

SAHA Capture Compound – A novel tool for the profiling of histone deacetylases and the identification of additional vorinostat binders

Anna K. Schrey, A. Diehl, J. Ungewiss, 2011, Proteomics.

Dasatinib, imatinib and staurosporine capture compounds - Complementary tools for the profiling of kinases by Capture Compound Mass Spectrometry (CCMS).

Anna K. Schrey, Jenny J. Fischer, M. Sefkow, 2011, Journal of proteomics.

Are meaningful predictions of toxicological outcomes in clinical trials based on in vitro diagnostics of preclinical drug candidates possible?

M. Dreger, F. Kroll, 2010, Future medicinal chemistry.

"Early prediction of drug toxicities that would have resulted in lower attrition rates in clinical trials has been unsuccessful, and clinical toxicity remains the main reason why drugs are failing."

M. Dreger, F. Kroll, 2010 .